These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 16336330

  • 1. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    Gutman S, Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Adamovich E.
    BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
    [Abstract] [Full Text] [Related]

  • 2. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2006 Jan 01; 64(1):136-43. PubMed ID: 16198062
    [Abstract] [Full Text] [Related]

  • 3. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A, Merrick GS, Butler WM, Wallner KE, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1367-82. PubMed ID: 15275722
    [Abstract] [Full Text] [Related]

  • 4. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Murray B, Allen Z, Lief JH, Galbreath RW.
    Brachytherapy; 2004 Aug 01; 3(1):22-9. PubMed ID: 15110310
    [Abstract] [Full Text] [Related]

  • 5. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
    Allen ZA, Merrick GS, Butler WM, Wallner KE, Kurko B, Anderson RL, Murray BC, Galbreath RW.
    Int J Radiat Oncol Biol Phys; 2005 Jul 15; 62(4):981-7. PubMed ID: 15989998
    [Abstract] [Full Text] [Related]

  • 6. Selecting patients with pretreatment postvoid residual urine volume less than 100 mL may favorably influence brachytherapy-related urinary morbidity.
    Beekman M, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW.
    Urology; 2005 Dec 15; 66(6):1266-70. PubMed ID: 16360455
    [Abstract] [Full Text] [Related]

  • 7. Brachytherapy-related dysuria.
    Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Lief JH.
    BJU Int; 2005 Mar 15; 95(4):597-602. PubMed ID: 15705087
    [Abstract] [Full Text] [Related]

  • 8. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
    Mabjeesh NJ, Chen J, Stenger A, Matzkin H.
    Urology; 2007 Sep 15; 70(3):548-53. PubMed ID: 17905113
    [Abstract] [Full Text] [Related]

  • 9. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J, Stock RG, Stone NN, Iannuzzi C, DeWyngaert JK.
    Radiat Oncol Investig; 1998 Sep 15; 6(3):135-41. PubMed ID: 9652912
    [Abstract] [Full Text] [Related]

  • 10. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M, Miller S, Moravan V, Pickles T, McKenzie M, Pai H, Liu M, Kwan W, Agranovich A, Spadinger I, Lapointe V, Halperin R, Morris WJ.
    Int J Radiat Oncol Biol Phys; 2009 Mar 15; 73(4):1023-32. PubMed ID: 19111402
    [Abstract] [Full Text] [Related]

  • 11. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW.
    Urology; 2002 Oct 15; 60(4):650-5. PubMed ID: 12385927
    [Abstract] [Full Text] [Related]

  • 12. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
    Williams SG, Millar JL, Duchesne GM, Dally MJ, Royce PL, Snow RM.
    Radiother Oncol; 2004 Oct 15; 73(1):33-8. PubMed ID: 15465143
    [Abstract] [Full Text] [Related]

  • 13. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
    Kollmeier MA, Stock RG, Cesaretti J, Stone NN.
    J Urol; 2005 Mar 15; 173(3):808-12. PubMed ID: 15711274
    [Abstract] [Full Text] [Related]

  • 14. Seed implant retention score predicts the risk of prolonged urinary retention after prostate brachytherapy.
    Lee HK, Adams MT, Shi Q, Basillote J, Lamonica J, Miranda L, Motta J.
    Int J Radiat Oncol Biol Phys; 2010 Apr 15; 76(5):1445-9. PubMed ID: 19553032
    [Abstract] [Full Text] [Related]

  • 15. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M, Studer G, Le L, McLean M, Yeung I, Pond G, Crook JM.
    Brachytherapy; 2007 Apr 15; 6(3):173-9. PubMed ID: 17681239
    [Abstract] [Full Text] [Related]

  • 16. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
    Lehrer S, Cesaretti J, Stone NN, Stock RG.
    BJU Int; 2006 Nov 15; 98(5):979-81. PubMed ID: 17034599
    [Abstract] [Full Text] [Related]

  • 17. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation.
    Acher PL, Popert R, Morris SL, Potters L, Austin-Smith SL, Johnson UH, Nichol JE, Beaney RP.
    BJU Int; 2007 May 15; 99(5):1066-71. PubMed ID: 17233801
    [Abstract] [Full Text] [Related]

  • 18. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds.
    Bottomley D, Ash D, Al-Qaisieh B, Carey B, Joseph J, St Clair S, Gould K.
    Radiother Oncol; 2007 Jan 15; 82(1):46-9. PubMed ID: 17161481
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy.
    Sarosdy MF.
    Cancer; 2004 Aug 15; 101(4):754-60. PubMed ID: 15305406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.